Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells

Off-target editing is one of the main safety concerns for the use of CRISPR-Cas9 genome editing in gene therapy. These unwanted modifications could lead to malignant transformation, which renders tumorigenicity assessment of gene therapy products indispensable. In this study, we established two in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemmens, Myriam, Fischer, Benoit, Zogg, Michael, Rodrigues, Lindsey, Kerr, Grainne, del Rio-Espinola, Alberto, Schaeffer, Fanny, Maddalo, Danilo, Dubost, Valerie, Piaia, Alessandro, Mueller, Arne, Plappert-Helbig, Ulla, Naumann, Ulrike, Haegele, Jasmin, Odermatt, Alex, Martus, Hans-Jörg, Libertini, Silvana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505356/
https://www.ncbi.nlm.nih.gov/pubmed/34703845
http://dx.doi.org/10.1016/j.omtm.2021.09.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505356/
https://www.ncbi.nlm.nih.gov/pubmed/34703845
http://dx.doi.org/10.1016/j.omtm.2021.09.004

Ejemplares similares